

March 16, 2020

To The Manager, Listing Department National Stock Exchange of India Plot no. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai- 400 051 Symbol: BLISSGVS	To The General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 506197
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for setting up "New state of the art Oral Solid Dosage Facility".

Dear Sir/Madam,

Pursuant to Regulation 30(6) read with Para B of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has completed the commissioning & qualification of Phase-I for its new state of the art multi-product facility situated at Palghar East in Maharashtra. This is the largest manufacturing unit of the Company in terms of planned production capacity when completed. It is equipped with state of the art process equipment & utilities with a large part of the manufacturing process automated for enhanced levels of productivity, efficiency & compliance while reducing manual intervention.


The unit is spread on an overall area of about 200,000 sq. ft. and is intended to further augment the production capacities for the Company. "We have a robust pipeline of formulations ready at our R&D unit for WHO Prequalification along with US and EU Markets for Tech-Transfer & Scale Up for this unit and we foresee a healthy business growth from our new Unit. In line with our commitment towards sustainability, a significant portion of the energy requirement of this facility will be met by captive solar power generation units." said Gagan Harsh Sharma, VP-Strategy & Business Development, Bliss GVS Pharma Limited.

The Company has received necessary permissions for the facility from the relevant authorities to commence tech-transfer/validation activities.

You are requested to provide wide dissemination to the above.

Thanking you,

Yours Faithfully,
For Bliss GVS Pharma Limited


S. N. Kamath
Managing Director
DIN: 00140593



Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,
Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory : Plot No. 10 & 11 Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.
Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com